Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Hodgkin Disease 1Burkitt Lymphoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

atezolizumab 3Trastuzumab 2tocilizumab 1spartalizumab 1pralsetinib 1pertuzumab 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1olaparib 1ipatasertib 1inavolisib 1fludarabine phosphate 1fludarabine 1entrectinib 1cemiplimab 1anlotinib 1alectinib 1adagrasib 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Filgrastim 1Docetaxel 1Cyclophosphamide 1Cetuximab 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × pegylated granulocyte colony-stimulating factor × 30 days × Clear all
NCT06926751 2026-05-07

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
132 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡